Seeking Alpha
20 Aug 2026, 05:19 UTC · 13w ago
Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform
Impact · against what's priced in
Trevi Therapeutics is positioned for growth following positive Phase II data and the commencement of pivotal trials for Haduvio across multiple indications. The ability to target a concentrated pulmonology network reduces commercialization risk and enhances the valuation of its specialty pharma transition.
- TRVI+0.70
No priced-in read yet
- In context
Positive Phase II data for both IPF and RCC, combined with the move into pivotal trials and a targeted specialty-first commercial strategy, significantly derisks the path to market.
Read from the article alone

Search tags




